Please login to the form below

Not currently logged in
Email:
Password:

Opdivo

This page shows the latest Opdivo news and features for those working in and with pharma, biotech and healthcare.

Opdivo improves survival in oesophageal cancer

Opdivo improves survival in oesophageal cancer

BMS said that while Opdivo plus Yervoy hit its OS primary endpoint, it missed the PFS co-primary endpoint. ... The US Food and Drug Administration (FDA) accepted a priority review for BMS’ Opdivo plus chemotherapy combination in stomach cancer earlier

Latest news

More from news
Approximately 155 fully matching, plus 230 partially matching documents found.

Latest Intelligence

  • Putting commercial intelligence at the heart of strategy Putting commercial intelligence at the heart of strategy

    Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The merger was completed shortly after BMS reported the first decline in quarterly sales of its immuno-oncology blockbuster Opdivo (nivolumab) since its launch five years ago, and 2020 is viewed ... Opdivo is being squeezed out of the market by Merck &Co/

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    Opdivo will be just behind on around $6.8bn, with more rapid growth for both therapies expected this year. ... Opdivo is not a contender as a monotherapy or combination with chemo in front-line NSCLC, having failed key trials in the last few years.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda. ... BMS looks unlikely to take the lead again, but Boerner can ensure Opdivo remains

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics